CFI-400945

  Cat. No.:  DC70300   Featured
Chemical Structure
1338806-73-7
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
CFI-400945 is a potent, highly selective PLK4 inhibitor with Ki of 0.26 nM and IC50 of 2.8 nM, does not significantly inhibits PLK1/2/3 at 50 uM; causes dysregulated centriole duplication, mitotic defects, and cell death in multiple cancer cell lines (A549 GI50=5 nM, OVCAR-3 GI50=18 nM); significantly inhibits human cancer xenografts; causes polyploidy, growth inhibition, and apoptotic death of murine and human lung cancer cells, despite expression of mutated KRAS or p53, produces supernumerary centrosomes and mitotic defects in lung cancer cells.
Cas No.: 1338806-73-7
Chemical Name: CFI-400945 (free base)
Synonyms: CFI-400945 (free base);CFI400945 free base;TL1UD860AA;NSC791966;s7552;SB17032;(2'S,3R)-2'-[3-[(E)-2-[4-[[(2S,6R)-2,6-dimethylmorpholin-4-yl]methyl]phenyl]ethenyl]-1H-indazol-6-yl]-5-methoxyspiro[1H-indole-3,1'-cyclopropane]-2-one;Spiro(cyclopropane-1,3'-(3H)indol)-2'(1'H)-one, 2-(3-((1E)-2-(4-(((2R,6S)-2,6-dimethyl-4-morpholinyl)methyl)phenyl)eth
SMILES: O=C1[C@]2(C3C([H])=C(C([H])=C([H])C=3N1[H])OC([H])([H])[H])C([H])([H])[C@@]2([H])C1C([H])=C([H])C2C(/C(/[H])=C(\[H])/C3C([H])=C([H])C(=C([H])C=3[H])C([H])([H])N3C([H])([H])[C@@]([H])(C([H])([H])[H])O[C@@]([H])(C([H])([H])[H])C3([H])[H])=NN([H])C=2C=1[H]
Formula: C33H34N4O3
M.Wt: 534.6481
Purity: >98%
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
MSDS
COA
LOT NO. DOWNLOAD
2018-0101
Cat. No. Product name Field of application
DC73219 Allopole Allopole is the first allosteric, specfic and cell-permeable inhibitor of the noncatalytic polo-box domain (PBD) of PLK1 (Polo-like kinase 1), Allopole is the prodrug of Allopole-A.
DC70300 CFI-400945 CFI-400945 is a potent, highly selective PLK4 inhibitor with Ki of 0.26 nM and IC50 of 2.8 nM, does not significantly inhibits PLK1/2/3 at 50 uM; causes dysregulated centriole duplication, mitotic defects, and cell death in multiple cancer cell lines (A549 GI50=5 nM, OVCAR-3 GI50=18 nM); significantly inhibits human cancer xenografts; causes polyploidy, growth inhibition, and apoptotic death of murine and human lung cancer cells, despite expression of mutated KRAS or p53, produces supernumerary centrosomes and mitotic defects in lung cancer cells.
DC9594 Poloxin Poloxin is a non-ATP competitive Polo-like Kinase 1 (PLK1) inhibitor that targets the polo-box domain.
DC8768 HMN-214 HMN-214(IVX214) is a potent PLK1 inhibitor an average IC50 of 0.12 μM.
X